Check out recent work of Calu Lab’s David Martin et al examining Psychedelic effects on NAc dopamine signaling of Pavlovian reward associations!

Something very very bad is happening to me or I am tired

From someone who has studied this field for over 2 decades, I can comfortably say that virtually everything said here is inaccurate. It is incredibly disturbing to me that someone claiming to be a scientist can talk with such authority on something they clearly know nothing about

So excited to have our most recent #dopamine paper led by @_sjmillard and Ivy Hoang out in Nature Neuroscience today! rdcu.be/dHL7l

Root lab is recruiting four research assistants to aid in stress-related research (jobs.colorado.edu/jobs/JobDetail…) and ongoing projects (jobs.colorado.edu/jobs/JobDetail…). Boulder is a great place to be, reach out if have questions!

A fear conditioned cue orchestrates a suite of behaviors in rats elifesciences.org/articles/82497

New research from our group on differences between VTA glutamate neuron subtypes in their signaling of rewarding and aversive experiences

Very excited for this paper to be out in Neuron . We opto stimulated specific inputs to the VTA and used snRNAseq to identify which neuronal subclusters were activated by each input. A fantastic collaboration with Rhiana C Simon, PhD and Stuber Lab cell.com/neuron/abstrac…

How can some people - like meditators and free divers - control their own heart rates?? An impossibly cool paper where the answer comes from training rats 🐀 to regulate their 🫀 Top-down brain circuits for operant bradycardia | Science science.org/doi/10.1126/sc…

Calu Lab’s David Martin et al study officially is out 🎉, Psychedelic effects on Dopamine signaling: nature.com/articles/s4138…

A feature-specific reward prediction error (RPE) model: individual VTA #dopamine neurons report RPEs for different aspects of an animal’s situation, explaining heterogeneity in DA signals Dr. Rachel Lee Yotam Sagiv Nathaniel Daw @IlanaWitten nature.com/articles/s4159…

Today in nature-- Monell Center researchers, led by AmberAlhadeff, share new findings that point towards a possible way to reduce adverse side effects of popular next-generation obesity medications like GLP1-based drugs, known as semaglutide and marketed as Ozempic® and Wegovy®

Drugs like Ozempic are great for weight loss, but they make some people feel sick. We discovered that the brain circuits mediating the appetite suppression are distinct from those that mediate nausea – a finding that may be leveraged to develop more selective GLP1-based drugs.

🚨 Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target sciencedirect.com/science/articl… Lorenzo Leggio Pharmacological Research NIDAnews NIAAA News NIH Intramural

Be mindful about axon collateralization! We have changed some experimental strategies based on this discovery. Proud to have the cover image for this journal issue and also a “Featured Article” designation! Happy times. jneurosci.org/content/44/31/…

Evidence is mounting that blockbuster anti-obesity drugs might also curb alcohol cravings, and more. go.nature.com/3XT8NrM

Hey NRSA recipients, this is the heroine who your awards are named after 👇💕

We found that in vivo peptide release and signaling gradually enhances the response of satiety-promoting hypothalamic neurons to each bite of food during a meal. These consequences of each bite take minutes to manifest, and could help explain why slow eating enhances satiety.

The fireworks in your mind. 🧠✨ This sparkling video shows the neurotransmitter glutamate being released into synapses, made possible by an indicator developed by Abhi Aggarwal, Kaspar Podgorski, and team. #HappyNewYear #NYE

Excited to share our newest paper led by kuldeep shrivastava out now in Nature Communications nature.com/articles/s4146… 1/